These data have resulted in a phase I/II clinical trial in which dabrafenib (BRAFi), trametinib (MEKi), and hydroxychloroquine (autophagy/lysosome inhibitor) are being tested in patients with advanced BRAF-mutant melanoma (BAMM: NCT02257424). This evidence concerns the gene BRAF and melanoma.